The crosstalk of mTOR/S6K1 and Hedgehog pathways.
暂无分享,去创建一个
Kenneth K Wang | J. Ajani | Tsung-Teh Wu | M. Hung | J. Hsu | W. Xia | J. Hsu | Yun Wu | Tzu-Hsuan Huang | Wei‐Chao Chang | Q. Ding | Yan Wang | Chung-Hsuan Chen | F. Tsai | N. Buttar | Dung-Fang Lee | C. Yen | J. Izzo | Chien-Chen Lai | Xuemei Wang | Dongping Liu | L. Huo | Jingyu Lang | Huamin Wang | A. Labaff | S. Miller | Chia‐Wei Li | Wei-Chao Chang | Jung-Mao Hsu
[1] F. D. de Sauvage,et al. Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists. , 2011, Cancer research.
[2] T. Curran,et al. The Hedgehog's tale: developing strategies for targeting cancer , 2011, Nature Reviews Cancer.
[3] J. Dufour,et al. Everolimus Augments the Effects of Sorafenib in a Syngeneic Orthotopic Model of Hepatocellular Carcinoma , 2011, Molecular Cancer Therapeutics.
[4] J. Manola,et al. Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors , 2010, Clinical Cancer Research.
[5] D. Sabatini,et al. mTOR: from growth signal integration to cancer, diabetes and ageing , 2010, Nature Reviews Molecular Cell Biology.
[6] William Pao,et al. Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[7] Jing Yuan,et al. Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma , 2010, Science Translational Medicine.
[8] A. Zask,et al. Recent advances in the development of selective, ATP-competitive inhibitors of mTOR. , 2010, Current opinion in drug discovery & development.
[9] Paula Chaves,et al. Verification and unmasking of widely used human esophageal adenocarcinoma cell lines. , 2010, Journal of the National Cancer Institute.
[10] M. Katoh,et al. Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. , 2009, Current molecular medicine.
[11] A. Lockhart,et al. Novel targets in esophageal and gastric cancer: beyond antiangiogenesis , 2009, Expert opinion on investigational drugs.
[12] Takao Kawabe,et al. Regulation of the hedgehog signaling by the mitogen‐activated protein kinase cascade in gastric cancer , 2009, Molecular carcinogenesis.
[13] J. Merchant,et al. Paracrine Hedgehog signaling in stomach and intestine: new roles for hedgehog in gastrointestinal patterning. , 2009, Gastroenterology.
[14] A. Jemal,et al. Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.
[15] M. Katoh,et al. Integrative genomic analyses on GLI1: positive regulation of GLI1 by Hedgehog-GLI, TGFbeta-Smads, and RTK-PI3K-AKT signals, and negative regulation of GLI1 by Notch-CSL-HES/HEY, and GPCR-Gs-PKA signals. , 2009, International journal of oncology.
[16] D. Jenkins. Hedgehog signalling: emerging evidence for non-canonical pathways. , 2009, Cellular signalling.
[17] F. D. de Sauvage,et al. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. , 2009, Trends in pharmacological sciences.
[18] S. Sleijfer,et al. The applicability of mTOR inhibition in solid tumors. , 2009, Current cancer drug targets.
[19] M. Hongo,et al. Epidemiology of esophageal cancer: Orient to Occident. Effects of chronology, geography and ethnicity , 2009, Journal of gastroenterology and hepatology.
[20] J. Ajani,et al. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Kenneth K Wang,et al. Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma. , 2008, Cancer research.
[22] Burton B. Yang,et al. MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression , 2007, Proceedings of the National Academy of Sciences.
[23] P. Hainaut,et al. Esophageal cancer: The precursors (Part II) , 2007 .
[24] G. Hortobagyi,et al. IKKβ Suppression of TSC1 Links Inflammation and Tumor Angiogenesis via the mTOR Pathway , 2007, Cell.
[25] David M Sabatini,et al. Defining the role of mTOR in cancer. , 2007, Cancer cell.
[26] P. Hainaut,et al. Esophageal cancer: Cases and causes (Part I) , 2007, Endoscopy.
[27] Barbara Stecca,et al. Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways , 2007, Proceedings of the National Academy of Sciences.
[28] M. Katoh,et al. Hedgehog signaling pathway and gastrointestinal stem cell signaling network (review). , 2006, International journal of molecular medicine.
[29] I. Screpanti,et al. Numb is a suppressor of Hedgehog signalling and targets Gli1 for Itch-dependent ubiquitination , 2006, Nature Cell Biology.
[30] J. Ajani,et al. Hedgehog: an Attribute to Tumor Regrowth after Chemoradiotherapy and a Target to Improve Radiation Response , 2006, Clinical Cancer Research.
[31] T. Ochiya,et al. Hedgehog signal activation in gastric pit cell and in diffuse-type gastric cancer. , 2006, Gastroenterology.
[32] Steven P. Gygi,et al. mTOR and S6K1 Mediate Assembly of the Translation Preinitiation Complex through Dynamic Protein Interchange and Ordered Phosphorylation Events , 2005, Cell.
[33] K. Caca,et al. Molecularly targeted therapy for gastrointestinal cancer. , 2005, Current cancer drug targets.
[34] Paul Tempst,et al. Phosphorylation and Functional Inactivation of TSC2 by Erk Implications for Tuberous Sclerosisand Cancer Pathogenesis , 2005, Cell.
[35] Yutaka Shimada,et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours , 2003, Nature.
[36] P. Ingham,et al. Hedgehog signaling in animal development: paradigms and principles. , 2001, Genes & development.
[37] L. Mayo,et al. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1 , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[38] J. Jankowski,et al. Inflammation promotes Barrett's metaplasia and cancer: a unique role for TNFα , 2001, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.
[39] M. Nakafuku,et al. A binding site for Gli proteins is essential for HNF-3beta floor plate enhancer activity in transgenics and can respond to Shh in vitro. , 1997, Development.
[40] Lee F. Peng,et al. Small-molecule modulators of the Sonic Hedgehog signaling pathway. , 2010, Molecular bioSystems.
[41] Gerald C. Chu,et al. GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. , 2009, Genes & development.
[42] Steven Y. Cheng,et al. Role and regulation of human tumor suppressor SUFU in Hedgehog signaling. , 2008, Advances in cancer research.
[43] W. Bushman. Hedgehog Signaling in Development and Cancer , 2007 .
[44] S. Schreiber,et al. Control of p70 S6 kinase by kinase activity of FRAP in vivo , 1995, Nature.